Global law firm Squire Patton Boggs has advised UK-based Clinigen, the global pathfinder accelerating patient access to critical medicines, in connection with its definitive agreement to acquire SSI Strategy, a trusted strategic consulting partner to biotech innovators.
This acquisition builds on Clinigen’s current growth momentum in the US market and brings together SSI’s strategic depth and established US and European footprint with Clinigen’s global operational reach in clinical trials supplies, managed access, and specialised commercialisation – creating a comprehensive global partner for the biopharma industry from early-stage strategy to commercialisation.
The Squire Patton Boggs team advising Clinigen was led by corporate partner Michael R. Trivisonno, with significant contributions from tax partner Mitch Thompson.
Clinigen’s full press release linked here.